Drug Profile

AM 831

Alternative Names: AM831; PCAP programme

Latest Information Update: 19 Jul 2012

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ACADIA Pharmaceuticals
Class Antipsychotics; Small molecules
Mechanism of Action Dopamine D2 receptor antagonists; Muscarinic M1 receptor agonists; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Schizophrenia

Most Recent Events

13 Jul 2012 Discontinued - Phase-I for Schizophrenia in USA (PO)
09 Nov 2011 Phase-I clinical trials in Schizophrenia in USA (PO)
07 Nov 2011 US FDA approves IND application for AM 831 in Schizophrenia

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com